☆ 4.1 Article

Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany - First data from the German NAFLD-Registry

ZEITSCHRIFT FUR GASTROENTEROLOGIE (2023)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease

Jennifer R. Kramer et al.

Summary: Patients with NAFLD and diabetes have a high risk of developing HCC. The study found that the use of metformin was associated with a reduced risk of developing HCC, while combination therapy was associated with an increased risk. Glycemic control can be a useful biomarker for stratifying HCC risk in these patients.

HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis

Ferenc Emil Mozes et al.

Summary: Liver biopsy is still necessary for fibrosis staging in patients with non-alcoholic fatty liver disease. This study evaluated the diagnostic performance of liver stiffness measurement, FIB-4 Index, and NAFLD Fibrosis Score, and showed that sequential combinations of markers can reduce the need for liver biopsies.

GUT (2022)

Add to Collection

Article Gastroenterology & Hepatology

Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population-Based Study in Germany

Yvonne Huber et al.

Summary: This study explores liver enzymes and surrogate scores of hepatic steatosis and advanced hepatic fibrosis in the German population. The findings show that elevated liver enzymes were seen in almost a fifth of the German population, and the prevalence of advanced fibrosis was estimated at 1%.

HEPATOLOGY COMMUNICATIONS (2022)

Add to Collection

Article Gastroenterology & Hepatology

Real-World Burden of Nonalcoholic Steatohepatitis

Andreas Geier et al.

Summary: In this study analyzing data from NASH patients in the United States, France, and Germany, it was found that NASH is associated with increased healthcare resource use and reduced HRQoL in symptomatic patients. The burden of NASH appears to be underestimated and further studies are needed to determine the burden of NASH by fibrosis stage and disease severity.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects

Javier Ampuero et al.

Summary: The study investigated the distribution of NASH and its components across fibrosis stages, revealing a decrease in steatohepatitis prevalence in advanced liver disease. However, most patients still showed inflammatory activity and metabolic disturbances. The risk of cirrhosis progression was similar between NASH and indeterminate NASH patients.

LIVER INTERNATIONAL (2021)

Add to Collection

Article Medicine, General & Internal

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

Philip N. Newsome et al.

Summary: This phase 2 trial demonstrated that treatment with semaglutide resulted in a significantly higher percentage of patients with NASH resolution compared to placebo in patients with NASH, but did not show a significant between-group difference in the percentage of patients with an improvement in fibrosis stage.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany

Ali Canbay et al.

Summary: In Germany, NAFLD patients are often underestimated, especially those with advanced liver diseases. Early identification and management strategies are crucial to prevent disease progression and limit the rising costs.

ANNALS OF TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Gastroenterology & Hepatology

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study

Philip N. Newsome et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care

Wolf Peter Hofmann et al.

JHEP REPORTS (2020)

Add to Collection

Article Oncology

Non-Alcoholic Steatohepatitis as a Risk Factor for Intrahepatic Cholangiocarcinoma and Its Prognostic Role

Stefania De Lorenzo et al.

CANCERS (2020)

Add to Collection

Review Gastroenterology & Hepatology

Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

Zobair Younossi et al.

HEPATOLOGY (2019)

Add to Collection

Article Endocrinology & Metabolism

Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study

Oana P. Zaharia et al.

LANCET DIABETES & ENDOCRINOLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

A 2-step fast-track elastometry service for advanced workup of nonalcoholic fatty liver disease (NAFLD) patients - single-center real-world experience of outpatient clinical practice

Mohamed Alsenbesy et al.

ZEITSCHRIFT FUR GASTROENTEROLOGIE (2019)

Add to Collection

Review Gastroenterology & Hepatology

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

Zobair Younossi et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030

Chris Estes et al.

JOURNAL OF HEPATOLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany

Christian Labenz et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study

Marcin Krawczyk et al.

JOURNAL OF LIPID RESEARCH (2017)

Add to Collection

Review Gastroenterology & Hepatology

Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis

Parambir S. Dulai et al.

HEPATOLOGY (2017)

Add to Collection

Article Medicine, Research & Experimental

Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study

A. S. Barritt et al.

CONTEMPORARY CLINICAL TRIALS (2017)

Add to Collection

Article Gastroenterology & Hepatology

Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study

Edith M. Koehler et al.

HEPATOLOGY (2016)

Add to Collection

Article Gastroenterology & Hepatology

Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis

Giovanni Targher et al.

JOURNAL OF HEPATOLOGY (2016)

Add to Collection

Article Gastroenterology & Hepatology

Liver transplantation in Germany

Frank Tacke et al.

LIVER TRANSPLANTATION (2016)

Add to Collection

Article Gastroenterology & Hepatology

S2k Guideline non-alcoholic fatty liver disease AWMF Register Nr. 021-025 Version January 2015, first edition

E. Roeb et al.

ZEITSCHRIFT FUR GASTROENTEROLOGIE (2015)

Add to Collection

Review Endocrinology & Metabolism

Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome

Hannele Yki-Jarvinen

LANCET DIABETES & ENDOCRINOLOGY (2014)

Add to Collection

Article Gastroenterology & Hepatology

A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis

Vlad Ratziu et al.

JOURNAL OF HEPATOLOGY (2011)

Add to Collection

Article Gastroenterology & Hepatology

High-Dose Ursodeoxycholic Acid Therapy for Nonalcoholic Steatohepatitis: A Double-Blind, Randomized, Placebo-Controlled Trial

Ulrich F. H. Leuschner et al.

HEPATOLOGY (2010)

Add to Collection

Article Gastroenterology & Hepatology

The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population

Giorgio Bedogni et al.

BMC GASTROENTEROLOGY (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.